EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Addition of probenecid to beta-lactam antibiotics in the treatment of skin and soft tissue infections: a systematic review

Claudette Hewitt, Martin John Llewelyn, Elizabeth Cross

Journal of Antimicrobial Chemotherapy · 2026-11-03 · 81 (12)

DOI: 10.1093/jac/dkag376 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background and Objectives Among patients presenting to hospital with skin and soft tissue infection (SSTI), up to 50% have already failed oral antibiotic treatment and 90% receive intravenous (IV) antibiotics. Probenecid prolongs serum concentrations of beta-lactam antibiotics. Probenecid-boosted oral treatment may be an alternative to IV. Alternatively, probenecid could allow less frequent dosing of narrow-spectrum IV agents (e.g. cefazolin), reducing dependence on ceftriaxone in ambulatory settings. This systematic review evaluated the effectiveness and safety of probenecid combined with beta-lactam antibiotics for SSTI treatment. Methods MEDLINE and EMBASE were searched through February 2026. Eligible studies assessed the addition of probenecid to beta-lactam therapy in human participants with SSTIs and reported clinical outcomes or adverse effects. Results Nine studies (over 1600 participants) were included, most evaluating once-daily IV cefazolin plus probenecid versus ceftriaxone or more frequent cefazolin dosing. Treatment success, failure, relapse and hospital admission rates were similar between groups, indicating that probenecid-boosted cefazolin performs comparably to standard regimens while offering a narrower-spectrum alternative to ceftriaxone. Evidence for oral beta-lactams plus probenecid was more limited but did not suggest inferiority. Adverse events, inconsistently reported, were generally mild and predominantly gastrointestinal, with possibly higher rates in the probenecid-containing regimens. Conclusions Current evidence suggests probenecid may enable once-daily IV cefazolin as an alternative to ceftriaxone for SSTI, supporting narrower-spectrum antibiotics in ambulatory care. Evidence for using oral beta-lactams plus probenecid remains limited. A robust RCT is needed to determine clinical non-inferiority and acceptability of adverse effects. If effective, this approach could reduce IV complications, healthcare attendance and costs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →